SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

TD52

Item No. 37744

CAS Registry No.:	1798328-24-1
Formal Name:	N^2,N^3-*bis*(3-ethynylphenyl)-2,3-quinoxalinediamine
MF:	$C_{24}H_{16}N_4$
FW:	360.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 237, 246, 277, 366 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

TD52 is supplied as a solid. A stock solution may be made by dissolving the TD52 in the solvent of choice, which should be purged with an inert gas. TD52 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of TD52 in these solvents is approximately 5 mg/ml.

Description

TD52 is a derivative of the EGFR tyrosine kinase inhibitor erlotinib (Item Nos. 10483 | 35517).[1] It decreases the viability of HA22T, Hep3B, PLC/PRF/5, and SK-HEP-1 hepatocellular carcinoma cells (IC_{50}s = 0.9, 0.9, 0.8, and 1.2 µM, respectively). TD52 induces apoptosis in a variety of cancer cells, including HA22T and Hep3B hepatocellular carcinoma and HCC1937 and MDA-MB-231 triple-negative breast cancer cells in a concentration-dependent manner.[1,2] TD52 (10 mg/kg per day) increases intratumoral protein phosphatase 2A (PP2A) activity, reduces intratumoral cancerous inhibitor of PP2A (CIP2A) and phosphorylated Akt levels, and reduces tumor growth in a PLC/PRF/5 mouse xenograft model.[1]

References

1. Yu, H.-C., Hung, M.-H., Chen, Y.-L., *et al.* Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. *Cell Death Dis.* **5(7),** e1359 (2014).
2. Liu, C.-Y., Huang, T.-T., Huang, C.-T., *et al.* EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. *Eur. J. Cancer* **72,** 112-123 (2017).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM